Cover
Cover - shares | 6 Months Ended | |
Jun. 30, 2022 | Aug. 19, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Jun. 30, 2022 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-55453 | |
Entity Registrant Name | ENDONOVO THERAPEUTICS, INC. | |
Entity Central Index Key | 0001528172 | |
Entity Tax Identification Number | 45-2552528 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 6320 Canoga Avenue | |
Entity Address, Address Line Two | 15th Floor | |
Entity Address, City or Town | Woodland Hills | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 91367 | |
City Area Code | (800) | |
Local Phone Number | 489-4774 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 152,477,537 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash | $ 85,936 | |
Accounts receivable, net of allowance for doubtful accounts of $0 | 945 | 944 |
Prepaid expenses and other current assets | 5,000 | 7,975 |
Total current assets | 5,945 | 94,855 |
Patents, net | 1,588,900 | 1,912,356 |
Total assets | 1,594,845 | 2,007,211 |
Current liabilities | ||
Accounts payable and accrued liabilities | 786,032 | 658,463 |
Accrued interest | 3,032,796 | 2,528,459 |
Deferred compensation | 4,210,261 | 3,891,361 |
Notes payable, net of discounts of $49,830 and $75,800 as of June 30, 2022, and December 31, 2021 | 7,237,204 | 7,055,030 |
Notes payable – former related party | 119,600 | 126,100 |
Derivative liability | 5,289,261 | 3,442,297 |
Total current liabilities | 20,675,154 | 17,701,710 |
Acquisition payable | 79,825 | 79,825 |
Total liabilities | 20,754,979 | 17,781,535 |
COMMITMENTS AND CONTINGENCIES, note 9 | ||
Shareholders’ deficit | ||
Preferred value | ||
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 150,427,538 and 74,498,761 shares issued and outstanding as of June 30, 2022, and December 31, 2021 | 15,042 | 7,449 |
Additional paid-in capital | 42,209,124 | 40,663,187 |
Stock subscriptions | (1,570) | (1,570) |
Accumulated deficit | (61,382,756) | (56,443,416) |
Total shareholders’ deficit | (19,160,134) | (15,774,324) |
Total liabilities and shareholders’ deficit | 1,594,845 | 2,007,211 |
Super AA Super Voting Preferred Stock [Member] | ||
Shareholders’ deficit | ||
Preferred value | 25 | 25 |
Series B Convertible Preferred Stock [Member] | ||
Shareholders’ deficit | ||
Preferred value | 1 | 1 |
Series C Convertible Preferred Stock [Member] | ||
Shareholders’ deficit | ||
Preferred value | ||
Series D Convertible Preferred Stock [Member] | ||
Shareholders’ deficit | ||
Preferred value |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Allowance for doubtful accounts receivable | $ 0 | $ 0 |
Discounts on notes payable current | $ 49,830 | $ 75,800 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 2,500,000,000 | 2,500,000,000 |
Common stock, shares issued | 150,427,538 | 74,498,761 |
Common stock, shares outstanding | 150,427,538 | 74,498,761 |
Super AA Super Voting Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 25,000 | 25,000 |
Preferred stock, shares outstanding | 25,000 | 25,000 |
Series B Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 50,000 | 50,000 |
Preferred stock, shares issued | 600 | 600 |
Preferred stock, shares outstanding | 600 | 600 |
Series C Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 8,000 | 8,000 |
Preferred stock, shares issued | 738 | 738 |
Preferred stock, shares outstanding | 738 | 738 |
Series D Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 20,000 | 20,000 |
Preferred stock, shares issued | 305 | 305 |
Preferred stock, shares outstanding | 305 | 305 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Income Statement [Abstract] | ||||
Revenue | $ 650 | $ 30,284 | $ 2,932 | $ 64,999 |
Cost of revenue | 383 | 500 | 1,097 | 3,021 |
Gross profit | 267 | 29,784 | 1,835 | 61,978 |
Operating expenses | 1,799,016 | 599,837 | 2,286,346 | 1,222,475 |
Loss from operations | (1,798,749) | (570,053) | (2,284,511) | (1,160,497) |
Other income (expense) | ||||
Change in fair value of derivative liability | (316,606) | (720,439) | (1,846,964) | (2,420,449) |
Gain on settlement of debt | 104,760 | 114,021 | 43,813 | 70,996 |
Other expense | (178,000) | (178,000) | ||
Interest expense, net | (337,536) | (120,198) | (673,678) | (467,600) |
Other expense | (727,382) | (726,616) | (2,654,829) | (2,817,053) |
Loss before income taxes | (2,526,131) | (1,296,669) | (4,939,340) | (3,977,550) |
Provision for income taxes | ||||
Net Loss | $ (2,526,131) | $ (1,296,669) | $ (4,939,340) | $ (3,977,550) |
Basic Loss per share | $ (0.02) | $ (0.02) | $ (0.05) | $ (0.08) |
Diluted Loss per share | $ (0.02) | $ (0.02) | $ (0.05) | $ (0.08) |
Weighted average common share outstanding: | ||||
Basic | 134,360,871 | 58,487,227 | 106,696,127 | 50,084,150 |
Diluted | 134,360,871 | 58,487,227 | 106,696,127 | 50,084,150 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Operating activities: | ||
Net Loss | $ (4,939,340) | $ (3,977,550) |
Adjustments to reconcile net loss to cash used in operating activities: | ||
Depreciation and amortization expense | 323,456 | 325,036 |
Stock compensation expense | 40,961 | |
Fair value of commitment shares issued with debt | 33,470 | |
Fair value of equity issued for services | 1,281,900 | |
Gain on extinguishment of debt | (43,813) | (70,996) |
Amortization of note discount and original issue discount | 59,138 | 72,751 |
Change in fair value of derivative liability | 1,846,964 | 2,420,449 |
Changes in assets and liabilities: | ||
Accounts receivable | (8,475) | |
Prepaid expenses and other current assets | 2,975 | 11,100 |
Account payable & accrued liabilities | 205,844 | 10,304 |
Accrued interest | 614,540 | 361,379 |
Deferred compensation | 318,900 | 355,689 |
Net cash used in operating activities | (329,436) | (425,882) |
Financing activities: | ||
Proceeds from the issuance of notes payable | 250,000 | 325,000 |
Repayments on former related-party of notes payable | (6,500) | (22,000) |
Repayments of convertible debt in cash | (8,000) | |
Proceeds from issuance of common stock and units | 126,000 | |
Net cash provided by financing activities | 243,500 | 421,000 |
Net decrease in cash | (85,936) | (4,882) |
Cash, beginning of year | 85,936 | 13,420 |
Cash, end of period | 8,538 | |
Supplemental disclosure of cash flow information: | ||
Cash paid for interest | ||
Cash paid for income taxes | ||
Non-Cash Investing and Financing Activities: | ||
Conversion of notes payable and accrued interest to common stock | 204,000 | 501,629 |
Conversion of Preferred C Stock to common stock | 33,333 | |
Debt discount from commitment shares issued with notes | $ 33,167 |
Condensed Consolidated Statem_3
Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - USD ($) | Preferred Stock [Member] Series AA Preferred Stock [Member] | Preferred Stock [Member] Series B Convertible Preferred Stock [Member] | Preferred Stock [Member] Series C Convertible Preferred Stock [Member] | Preferred Stock [Member] Series D Convertible Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Subscription Receivable [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Dec. 31, 2020 | $ 25 | $ 1 | $ 2,453 | $ 38,963,827 | $ (1,570) | $ (53,338,522) | $ (14,373,786) | ||
Beginning balance, shares at Dec. 31, 2020 | 25,000 | 600 | 763 | 305 | 24,536,689 | ||||
Shares issued for conversion of notes payable and accrued interest | $ 1,769 | 831,429 | 833,198 | ||||||
Shares issued for conversion of notes payable and accrued interest, shares | 17,686,548 | ||||||||
Net loss | (2,680,881) | (2,680,881) | |||||||
Shares issued as commitment to note holders | $ 230 | 101,652 | 101,882 | ||||||
Shares issued as commitment to note holders, shares | 2,300,334 | ||||||||
Common stock issued for cash | $ 700 | 125,300 | 126,000 | ||||||
Common stock issued for cash, shares | 7,000,000 | ||||||||
Valuation of stock options issued for services | 20,471 | 20,471 | |||||||
Ending balance, value at Mar. 31, 2021 | $ 25 | $ 1 | $ 5,152 | 40,042,679 | (1,570) | (56,019,403) | (15,973,116) | ||
Ending balance, shares at Mar. 31, 2021 | 25,000 | 600 | 763 | 305 | 51,523,571 | ||||
Beginning balance, value at Dec. 31, 2020 | $ 25 | $ 1 | $ 2,453 | 38,963,827 | (1,570) | (53,338,522) | (14,373,786) | ||
Beginning balance, shares at Dec. 31, 2020 | 25,000 | 600 | 763 | 305 | 24,536,689 | ||||
Net loss | (3,977,550) | ||||||||
Ending balance, value at Jun. 30, 2021 | $ 25 | $ 1 | $ 6,067 | 40,327,526 | (1,570) | 57,316,072 | (16,984,023) | ||
Ending balance, shares at Jun. 30, 2021 | 25,000 | 600 | 738 | 305 | 60,659,771 | ||||
Beginning balance, value at Mar. 31, 2021 | $ 25 | $ 1 | $ 5,152 | 40,042,679 | (1,570) | (56,019,403) | (15,973,116) | ||
Beginning balance, shares at Mar. 31, 2021 | 25,000 | 600 | 763 | 305 | 51,523,571 | ||||
Shares issued for conversion of notes payable and accrued interest | $ 381 | 116,165 | 116,546 | ||||||
Shares issued for conversion of notes payable and accrued interest, shares | 3,804,103 | ||||||||
Net loss | (1,296,669) | (1,296,669) | |||||||
Shares issued as commitment to note holders | $ 20 | 6,280 | 6,300 | ||||||
Shares issued as commitment to note holders, shares | 200,000 | ||||||||
Valuation of stock options issued for services | 20,491 | 20,491 | |||||||
Shares issued for conversion of Preferred Series C to Common share | $ 111 | (111) | |||||||
Shares issued for conversion of Preferred Series C to Common share, shares | (25) | 1,111,111 | |||||||
Common Shares issued for debt settlement | $ 152 | 57,576 | 57,728 | ||||||
Shares issued as settlement of debt with former related party | $ 251 | 84,446 | 84,697 | ||||||
Shares issued as settlement of debt with former related party, shares | 2,505,834 | ||||||||
Ending balance, value at Jun. 30, 2021 | $ 25 | $ 1 | $ 6,067 | 40,327,526 | (1,570) | 57,316,072 | (16,984,023) | ||
Ending balance, shares at Jun. 30, 2021 | 25,000 | 600 | 738 | 305 | 60,659,771 | ||||
Beginning balance, value at Dec. 31, 2021 | $ 25 | $ 1 | $ 7,449 | 40,663,187 | (1,570) | (56,443,416) | (15,774,324) | ||
Beginning balance, shares at Dec. 31, 2021 | 25,000 | 600 | 738 | 305 | 74,498,761 | ||||
Shares issued for conversion of notes payable and accrued interest | $ 370 | 88,430 | 88,800 | ||||||
Shares issued for conversion of notes payable and accrued interest, shares | 3,700,000 | ||||||||
Common stock issued for settlement of debt | $ 243 | 45,904 | 46,147 | ||||||
Common stock issued for settlement of debt, shares | 2,428,777 | ||||||||
Issuance of commitment shares in connection with promissory note | $ 70 | 15,680 | 15,750 | ||||||
Issuance of commitment shares in connection with promissory note, shares | 700,000 | ||||||||
Net loss | (2,413,209) | (2,413,409) | |||||||
Common Shares issued for debt settlement, shares | 1,515,152 | ||||||||
Ending balance, value at Mar. 31, 2022 | $ 25 | $ 1 | $ 8,132 | 40,813,201 | (1,570) | (58,856,625) | (18,036,836) | ||
Ending balance, shares at Mar. 31, 2022 | 25,000 | 600 | 738 | 305 | 81,327,538 | ||||
Beginning balance, value at Dec. 31, 2021 | $ 25 | $ 1 | $ 7,449 | 40,663,187 | (1,570) | (56,443,416) | (15,774,324) | ||
Beginning balance, shares at Dec. 31, 2021 | 25,000 | 600 | 738 | 305 | 74,498,761 | ||||
Net loss | (4,939,340) | ||||||||
Common Shares issued for services | $ 1,281,900 | ||||||||
Common Shares issued for services, shares | 62,250,000 | ||||||||
Ending balance, value at Jun. 30, 2022 | $ 25 | $ 1 | $ 15,042 | 42,209,124 | (1,570) | 61,382,756 | $ (19,160,134) | ||
Ending balance, shares at Jun. 30, 2022 | 25,000 | 600 | 305 | 150,427,538 | |||||
Beginning balance, value at Mar. 31, 2022 | $ 25 | $ 1 | $ 8,132 | 40,813,201 | (1,570) | (58,856,625) | (18,036,836) | ||
Beginning balance, shares at Mar. 31, 2022 | 25,000 | 600 | 738 | 305 | 81,327,538 | ||||
Shares issued for conversion of notes payable and accrued interest | $ 650 | 114,550 | 115,200 | ||||||
Shares issued for conversion of notes payable and accrued interest, shares | 6,500,000 | ||||||||
Issuance of commitment shares in connection with promissory note | $ 35 | 5,698 | 5,733 | ||||||
Issuance of commitment shares in connection with promissory note, shares | 350,000 | ||||||||
Net loss | (2,526,131) | (2,526,131) | |||||||
Common Shares issued for services | $ 6,225 | 1,275,675 | 1,281,900 | ||||||
Common Shares issued for services, shares | 62,250,000 | ||||||||
Ending balance, value at Jun. 30, 2022 | $ 25 | $ 1 | $ 15,042 | $ 42,209,124 | $ (1,570) | $ 61,382,756 | $ (19,160,134) | ||
Ending balance, shares at Jun. 30, 2022 | 25,000 | 600 | 305 | 150,427,538 |
Organization and Nature of Busi
Organization and Nature of Business | 6 Months Ended |
Jun. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Nature of Business | Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV). The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders). The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke. Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical ® ® bioelectricity |
Summary of significant accounti
Summary of significant accounting policies | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Summary of significant accounting policies | Note 2 – Summary of significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2022, and 2021, are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2022. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable. As of June 30, 2022, the Company had cash of $ 0 20.7 0.3 61.4 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) During the six months ended June 30, 2022, the Company has raised approximately $ 0.3 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the three months ended June 30, 2022, include stock options, warrants, and notes payable. The Company has 513,730 2,000 3,013,730 28,309 Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Newly Adopted Accounting Principles In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s condensed consolidated results of operations, financial position, and cash flows. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements. |
Revenue Recognition
Revenue Recognition | 6 Months Ended |
Jun. 30, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition | Note 3 - Revenue Recognition Contracts with Customers The Company adopted ASC 606, Revenue from Contracts with Customers . The Company routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Sources of Revenue The Company has identified the following revenues by revenue source: 1. Medical care providers For the three and six months ended June 30, 2022, and 2021, the sources of revenue were as follows: Schedule of Source of Revenue Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Direct sales- medical care providers, gross $ 650 $ 30,284 $ 2,932 $ 64,999 Total sources of revenue $ 650 $ 30,284 $ 2,932 $ 64,999 Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) |
Patents
Patents | 6 Months Ended |
Jun. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Patents | Note 4 – Patents In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $ 4,500,000 2024 Schedule of Patents June 30, December 31, Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 2,911,100 2,587,644 Patents, net $ 1,588,900 $ 1,912,356 Amortization expense associated with patents was $ 323,456 The estimated future amortization expense related to patents as of June 30, 2022, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending June 30, Amount 2023 $ 646,910 2024 646,910 2025 295,080 Total $ 1,588,900 |
Notes Payable
Notes Payable | 6 Months Ended |
Jun. 30, 2022 | |
Debt Disclosure [Abstract] | |
Notes Payable | Note 5- Notes Payable Activity for the six months ended June 30, 2022 Fixed rates Notes During the six months ended June 30, 2022, the Company issued three (3) fixed rate promissory notes totaling $ 250,000 250,000 original terms of nine months and interest rates of 15 As of June 30, 2022, the Company has sixteen (16) fixed-rate promissory notes with an outstanding balance of $ 1,891,204 1,116,204 In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $ 500,000 25,000 10 624,903 During the six months ended June 30, 2022, the Company converted $ 110,204 93,796 10,200,000 As of June 30, 2022, the Company has a total of sixteen (16) fixed-rate notes, of which twelve (12) for total principal amount of $ 1,250,000 15 178,000 Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15 121,000 Variable-rate notes The gross amount of all convertible notes with variable conversion rates outstanding as of June 30, 2022, is $ 4,770,926 4,770,926 Activity for the six months ended June 30, 2021 During the six months ended June 30, 2021, the Company issued four (4) fixed rate promissory notes totaling $ 325,000 325,000 original terms of twelve months and interest rates of 15 During the six months ended June 30, 2021, the Company amended the terms of two of its promissory notes to accelerate the conversion feature and amend the conversion price of the instruments. The Company recorded the modification in accordance with ASC 470-50 Debt-Modifications and Extinguishments 58,407 During the six months ended June 30, 2021, the Company settled one of its promissory note by issuing 1,515,152 128,000 During the six months ended June 30, 2021, the Company paid $ 8,000 During the six months ended June 30, 2021, the Company converted $ 282,850 91,485 21,490,651 The gross amount of all convertible notes with variable conversion rates outstanding at June 30, 2021 is $ 4,770,926 2,660,476 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Fixed Rate note (former related party) Notes payable to a former related party in the aggregate amount of $ 119,600 10 12 6,500 As of June 30, 2022, and December 31, 2021, the notes payable activity was as follows: Schedule of Notes Payable June 30, December 31, Notes payable at beginning of period $ 7,256,930 $ 6,835,196 Notes payable issued 250,000 950,000 Repayments of notes payable in cash (6,500 ) (16,900 ) Settlements on note payable - (117,770 ) Less amounts converted to stock (93,796 ) (393,596 ) Notes payable at end of period 7,406,634 7,256,930 Less debt discount (49,830 ) (75,800 ) $ 7,356,804 $ 7,181,730 Notes payable issued to a former related party $ 119,600 $ 126,100 Notes payable issued to non-related parties $ 7,237,204 $ 7,055,030 The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former Related party Non-related parties Total Past due $ 119,600 $ 6,512,034 $ 6,631,634 June 30, 2022 - 775,000 775,000 $ 119,600 $ 7,287,034 $ 7,406,634 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) |
Shareholders_ Deficit
Shareholders’ Deficit | 6 Months Ended |
Jun. 30, 2022 | |
Equity [Abstract] | |
Shareholders’ Deficit | Note 6 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Shares Authorized Number of Shares Outstanding at June 30, 2022 Par Liquidation Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 305 $ 0.0001 $ 1,000 Undesignated 3,922,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million ( 1,000,000 0.001 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company 25,000 Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 75 three-year 150 100 600 Series C Convertible Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 20.00 1,000 the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $ 1,000 There was no activity during the six months ended June 30, 2022. As of June 30, 2022, there are 738 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Series D Convertible Preferred Stock On November 11, 2019, the Company filed a certificate of designation for 20,000 0.01 The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $ 1,000 305 Common Stock Activity during the six months ended June 30, 2022 During the six months ended June 30, 2022, the Company issued 10,200,000 93,796 110,204 During the six months ended June 30, 2022, the Company issued 2,428,777 During the six months ended June 30, 2022, the Company issued 1,050,000 During the six months ended June 30, 2022, the Company issued 62,250,000 1,281,900 Activity during the six months ended June 30, 2021 During the six months ended June 30, 2021, the Company issued 21,490,651 374,335 During the six months ended June 30, 2021, the Company issued 2,500,334 During the six months ended June 30, 2021, the Company issued 7,000,000 126,000 During the six months ended June 30, 2021, the Company issued 1,111,111 33,333 During the six months ended June 30, 2021, the Company issued 4,020,986 142,424 2,505,834 84,697 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Stock Options The balance of all stock options outstanding as of June 30, 2022, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2022 513,730 $ 1.43 0.76 - Granted - $ - - - Cancelled - $ - - - Exercised - $ - - - Outstanding at June 30, 2022 513,730 $ 1.43 0.26 $ - Exercisable at June 30, 2022 513,730 $ 1.43 0.26 $ - Share-based compensation expense for the six months ended June 30, 2022, and 2021, totaled $ 0 40,961 Warrants The balance of all warrants outstanding as of June 30, 2022, is as follows: Schedule of Warrants Outstanding Outstanding Warrants Weighted Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at January 1, 2022 22,200 $ 59.25 0.32 Granted - $ - - Cancelled (20,200 ) $ 60.17 - Exercised - $ - Outstanding at June 30, 2022 2,000 $ 50.00 0.72 Exercisable at June 30, 2022 2,000 $ 50.00 0.72 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) |
Related Party and former relate
Related Party and former related parties Transactions | 6 Months Ended |
Jun. 30, 2022 | |
Related Party Transactions [Abstract] | |
Related Party and former related parties Transactions | Note 7 – Related Party and former related parties Transactions One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2022, the balance of the deferred compensation was $ 454,818 150,000 89,000 One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2022, the balance of his deferred compensation was $ 632,257 From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at June 30, 2022, was $ 925 5,662 4,862 As of June 30, 2022, notes payable remained outstanding to the former President of the Company, in the amount of $ 119,600 74,180 |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 8 – Fair Value Measurements The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Schedule of Conversion Feature Using Black Scholes Option Pricing Model Six months ended June 30, 2022 2021 Expected term 1 months 1 4 months Exercise price $ 0.004 0.015 $ 0.012 0.028 Expected volatility 153 169 182 206 Expected dividends None None Risk-free interest rate 1.63 2.80 0.07 0.13 Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the six months ended June 30, 2022: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2021 $ 3,442,297 Extinguishment - Change in estimated fair value 1,846,964 Balance June 30, 2022 $ 5,289,261 Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2022: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Active Significant Other Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total As of June 30, 2022 Derivative liability $ - $ - $ 5,289,261 $ 5,289,261 Total $ - $ - $ 5,289,261 $ 5,289,261 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 9 – Commitments and Contingencies Legal Matters We were defendants in a case entitled Auctus Fund, LLC v. Endonovo Therapeutics, Inc. et.al 20-cv-11286-PBS 275,250 500,000 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of June 30, 2022, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity. |
Concentrations
Concentrations | 6 Months Ended |
Jun. 30, 2022 | |
Risks and Uncertainties [Abstract] | |
Concentrations | Note 10 – Concentrations Sales During the six months ended June 30, 2022, we had two significant customers, which accounted for approximately 72 Supplier We also have a single source for our bioelectric medical devices, which account for 100 Accounts Receivable At June 30, 2022, we had two customers which accounted for approximately 100 |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 11 – Subsequent Events Management has evaluated events that have occurred subsequent to the date of these consolidated condensed financial statements and has determined that, other than those listed below, no such reportable subsequent events exist through the date the financial statements were issued in accordance with FASB ASC Topic 855, “Subsequent Events.” Subsequent to June 30, 2022, the Company entered into convertible fixed-rate promissory notes for a total amount of $ 150,000 Subsequent to June 30, 2022, the Company issued 2,050,000 Subsequent to June 30, 2022, pursuant to a settlement agreement between the parties the claims and counterclaims in the litigation have been dismissed without prejudice and the note is no longer outstanding with Auctus Fund LLC. |
Summary of significant accoun_2
Summary of significant accounting policies (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2022, and 2021, are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2022. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. |
Liquidity and Going Concern | Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable. As of June 30, 2022, the Company had cash of $ 0 20.7 0.3 61.4 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) During the six months ended June 30, 2022, the Company has raised approximately $ 0.3 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. |
Earnings (Loss) Per Share | Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the three months ended June 30, 2022, include stock options, warrants, and notes payable. The Company has 513,730 2,000 3,013,730 28,309 |
Accounts Receivable | Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) |
Newly Adopted Accounting Principles | Newly Adopted Accounting Principles In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s condensed consolidated results of operations, financial position, and cash flows. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements. |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Source of Revenue | For the three and six months ended June 30, 2022, and 2021, the sources of revenue were as follows: Schedule of Source of Revenue Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Direct sales- medical care providers, gross $ 650 $ 30,284 $ 2,932 $ 64,999 Total sources of revenue $ 650 $ 30,284 $ 2,932 $ 64,999 |
Patents (Tables)
Patents (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Patents | Schedule of Patents June 30, December 31, Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 2,911,100 2,587,644 Patents, net $ 1,588,900 $ 1,912,356 |
Schedule of Estimated Future Amortization Expense | The estimated future amortization expense related to patents as of June 30, 2022, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending June 30, Amount 2023 $ 646,910 2024 646,910 2025 295,080 Total $ 1,588,900 |
Notes Payable (Tables)
Notes Payable (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of Notes Payable | As of June 30, 2022, and December 31, 2021, the notes payable activity was as follows: Schedule of Notes Payable June 30, December 31, Notes payable at beginning of period $ 7,256,930 $ 6,835,196 Notes payable issued 250,000 950,000 Repayments of notes payable in cash (6,500 ) (16,900 ) Settlements on note payable - (117,770 ) Less amounts converted to stock (93,796 ) (393,596 ) Notes payable at end of period 7,406,634 7,256,930 Less debt discount (49,830 ) (75,800 ) $ 7,356,804 $ 7,181,730 Notes payable issued to a former related party $ 119,600 $ 126,100 Notes payable issued to non-related parties $ 7,237,204 $ 7,055,030 |
Schedule of Maturity Dates of Notes Payable | The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former Related party Non-related parties Total Past due $ 119,600 $ 6,512,034 $ 6,631,634 June 30, 2022 - 775,000 775,000 $ 119,600 $ 7,287,034 $ 7,406,634 |
Shareholders_ Deficit (Tables)
Shareholders’ Deficit (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Equity [Abstract] | |
Schedule of Preferred Stock | Schedule of Preferred Stock Number of Shares Authorized Number of Shares Outstanding at June 30, 2022 Par Liquidation Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 305 $ 0.0001 $ 1,000 Undesignated 3,922,000 - - - |
Schedule of Stock Options Outstanding | The balance of all stock options outstanding as of June 30, 2022, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2022 513,730 $ 1.43 0.76 - Granted - $ - - - Cancelled - $ - - - Exercised - $ - - - Outstanding at June 30, 2022 513,730 $ 1.43 0.26 $ - Exercisable at June 30, 2022 513,730 $ 1.43 0.26 $ - |
Schedule of Warrants Outstanding | The balance of all warrants outstanding as of June 30, 2022, is as follows: Schedule of Warrants Outstanding Outstanding Warrants Weighted Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at January 1, 2022 22,200 $ 59.25 0.32 Granted - $ - - Cancelled (20,200 ) $ 60.17 - Exercised - $ - Outstanding at June 30, 2022 2,000 $ 50.00 0.72 Exercisable at June 30, 2022 2,000 $ 50.00 0.72 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of Conversion Feature Using Black Scholes Option Pricing Model | Schedule of Conversion Feature Using Black Scholes Option Pricing Model Six months ended June 30, 2022 2021 Expected term 1 months 1 4 months Exercise price $ 0.004 0.015 $ 0.012 0.028 Expected volatility 153 169 182 206 Expected dividends None None Risk-free interest rate 1.63 2.80 0.07 0.13 Forfeitures None None |
Schedule of Fair Value of Derivative Liability | The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the six months ended June 30, 2022: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2021 $ 3,442,297 Extinguishment - Change in estimated fair value 1,846,964 Balance June 30, 2022 $ 5,289,261 |
Schedule of Liabilities Significant Unobservable Inputs | The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2022: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Active Significant Other Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total As of June 30, 2022 Derivative liability $ - $ - $ 5,289,261 $ 5,289,261 Total $ - $ - $ 5,289,261 $ 5,289,261 |
Summary of significant accoun_3
Summary of significant accounting policies (Details Narrative) - USD ($) | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Cash | $ 0 | ||
Working capital | 20,700,000 | ||
Net Cash Provided by (Used in) Operating Activities | 329,436 | $ 425,882 | |
Accumulated deficit | 61,382,756 | $ 56,443,416 | |
Proceeds from debt and equity financing | 300,000 | ||
Accounts Receivable, Allowance for Credit Loss, Current | $ 0 | $ 0 | |
Share-Based Payment Arrangement, Option [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Anti dilutive shares | 513,730 | 3,013,730 | |
Warrant [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Anti dilutive shares | 2,000 | 28,309 |
Schedule of Source of Revenue (
Schedule of Source of Revenue (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Disaggregation of Revenue [Line Items] | ||||
Total sources of revenue | $ 650 | $ 30,284 | $ 2,932 | $ 64,999 |
Direct Sales- Medical Care Providers [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Total sources of revenue | $ 650 | $ 30,284 | $ 2,932 | $ 64,999 |
Schedule of Patents (Details)
Schedule of Patents (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Patents | $ 4,500,000 | $ 4,500,000 |
Less accumulated amortization | 2,911,100 | 2,587,644 |
Patents, net | $ 1,588,900 | $ 1,912,356 |
Schedule of Estimated Future Am
Schedule of Estimated Future Amortization Expense (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2023 | $ 646,910 | |
2024 | 646,910 | |
2025 | 295,080 | |
Patents, net | $ 1,588,900 | $ 1,912,356 |
Patents (Details Narrative)
Patents (Details Narrative) - USD ($) | 1 Months Ended | 6 Months Ended | |
Dec. 31, 2017 | Jun. 30, 2022 | Jun. 30, 2021 | |
Amortization expense | $ 323,456 | $ 323,456 | |
Rio Grande Neurosciences, Inc. [Member] | |||
Acquisition of patents | $ 4,500,000 | ||
Patents expiration period | 2024 |
Schedule of Notes Payable (Deta
Schedule of Notes Payable (Details) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Debt Disclosure [Abstract] | ||
Notes payable at beginning of period | $ 7,256,930 | $ 6,835,196 |
Notes payable issued | 250,000 | 950,000 |
Repayments of notes payable in cash | (6,500) | (16,900) |
Settlements on note payable | (117,770) | |
Less amounts converted to stock | (93,796) | (393,596) |
Notes payable at end of period | 7,406,634 | 7,256,930 |
Less debt discount | (49,830) | (75,800) |
Note payable, net | 7,356,804 | 7,181,730 |
Notes payable issued to a former related party | 119,600 | 126,100 |
Notes payable issued to non-related parties | $ 7,237,204 | $ 7,055,030 |
Schedule of Maturity Dates of N
Schedule of Maturity Dates of Notes Payable (Details) | Jun. 30, 2022 USD ($) |
Defined Benefit Plan Disclosure [Line Items] | |
Past due | $ 6,631,634 |
June 30, 2022 | 775,000 |
Total | 7,406,634 |
Former Related Party [Member] | |
Defined Benefit Plan Disclosure [Line Items] | |
Past due | 119,600 |
June 30, 2022 | |
Total | 119,600 |
Non Related Parties [Member] | |
Defined Benefit Plan Disclosure [Line Items] | |
Past due | 6,512,034 |
June 30, 2022 | 775,000 |
Total | $ 7,287,034 |
Notes Payable (Details Narrativ
Notes Payable (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||||||||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Aug. 31, 2015 | Oct. 31, 2014 | Jul. 31, 2014 | Oct. 31, 2013 | |
Short-Term Debt [Line Items] | ||||||||||
Note payable | $ 7,406,634 | $ 7,406,634 | $ 7,256,930 | $ 6,835,196 | ||||||
Proceeds from Notes Payable | $ 250,000 | $ 325,000 | ||||||||
Debt instrument, interest rate | 10% | 10% | 10% | 10% | ||||||
Percentage of cash premium | 15% | |||||||||
Prepayment penalty | 121,000 | $ 121,000 | ||||||||
Gain on debt extinguishment | 104,760 | $ 114,021 | 43,813 | 70,996 | ||||||
Note payable related parties | 119,600 | 119,600 | 126,100 | |||||||
Gain (Loss) on Derivative Instruments [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Gain on debt extinguishment | 58,407 | |||||||||
Private Placement [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Note payable | 624,903 | 624,903 | $ 624,903 | |||||||
Maximum [Member] | Private Placement [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Note payable | $ 500,000 | $ 500,000 | $ 500,000 | $ 500,000 | ||||||
Minimum [Member] | Private Placement [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Note payable | $ 25,000 | $ 25,000 | $ 25,000 | $ 25,000 | ||||||
One Promissory Notes [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Note payable | $ 250,000 | 250,000 | ||||||||
Proceeds from Notes Payable | $ 250,000 | |||||||||
Debt instrument description | original terms of nine months and interest rates of 15%. The holder of the promissory note can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, six-month after issuance date | |||||||||
Debt instrument, interest rate | 15% | 15% | ||||||||
Fixed Rated Notes [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Note payable | $ 1,891,204 | $ 1,891,204 | ||||||||
Debt conversion, value | 110,204 | |||||||||
Accrued interest | 93,796 | $ 93,796 | ||||||||
Debt conversion, stock issued | 10,200,000 | |||||||||
Fixed Rated Notes [Member] | Past Maturity [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Note payable | 1,116,204 | $ 1,116,204 | ||||||||
Sixteen Fixed Rate [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Accrued interest | 178,000 | 178,000 | ||||||||
Debt instrument, face amount | 1,250,000 | $ 1,250,000 | ||||||||
Profit reselling conversion shares rate | 15% | |||||||||
Convertible Notes [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Convertible Debt | 4,770,926 | $ 4,770,926 | ||||||||
Convertible Notes [Member] | Past Maturity [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Convertible Debt | 4,770,926 | 4,770,926 | ||||||||
Four Fixed Promissory Notes [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Note payable | $ 325,000 | 325,000 | ||||||||
Proceeds from Notes Payable | $ 325,000 | |||||||||
Debt instrument description | original terms of twelve months and interest rates of 15%. The holders of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features | |||||||||
Debt instrument, interest rate | 15% | 15% | ||||||||
Promissory Notes [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Note payable | $ 1,515,152 | $ 1,515,152 | ||||||||
Debt conversion, value | 282,850 | |||||||||
Accrued interest | 91,485 | 91,485 | ||||||||
Gain on debt extinguishment | 128,000 | |||||||||
Principal payment of debt | $ 8,000 | |||||||||
Debt conversion, stock issued | 21,490,651 | |||||||||
Convertible Debentures One [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Convertible Debt | 4,770,926 | $ 4,770,926 | ||||||||
Convertible Debentures One [Member] | Past Maturity [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Convertible Debt | $ 2,660,476 | $ 2,660,476 | ||||||||
Notes Payable [Member] | Former Related Party [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Principal payment of debt | 6,500 | |||||||||
Note payable related parties | $ 119,600 | $ 119,600 | ||||||||
Notes Payable [Member] | Maximum [Member] | Former Related Party [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Debt instrument, interest rate | 12% | 12% | ||||||||
Notes Payable [Member] | Minimum [Member] | Former Related Party [Member] | ||||||||||
Short-Term Debt [Line Items] | ||||||||||
Debt instrument, interest rate | 10% | 10% |
Schedule of Preferred Stock (De
Schedule of Preferred Stock (Details) | Jun. 30, 2022 USD ($) $ / shares shares |
Series AA [Member] | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |
Number of shares authorized | 1,000,000 |
Number of shares outstanding | 25,000 |
Par value | $ / shares | $ 0.0010 |
Liquidation value | $ | |
Preferred Series B [Member] | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |
Number of shares authorized | 50,000 |
Number of shares outstanding | 600 |
Par value | $ / shares | $ 0.0001 |
Liquidation value | $ | $ 100 |
Preferred Series C [Member] | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |
Number of shares authorized | 8,000 |
Number of shares outstanding | 738 |
Par value | $ / shares | $ 0.0001 |
Liquidation value | $ | $ 1,000 |
Preferred Series D [Member] | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |
Number of shares authorized | 20,000 |
Number of shares outstanding | 305 |
Par value | $ / shares | $ 0.0001 |
Liquidation value | $ | $ 1,000 |
Undesignated [Member] | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |
Number of shares authorized | 3,922,000 |
Number of shares outstanding | |
Par value | $ / shares | |
Liquidation value | $ |
Schedule of Stock Options Outst
Schedule of Stock Options Outstanding (Details) - Equity Option [Member] | 6 Months Ended |
Jun. 30, 2022 USD ($) $ / shares shares | |
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] | |
Stock Option Outstanding, Beginning Balance | shares | 513,730 |
Weighted Average Exercise Price, Beginning Balance | $ / shares | $ 1.43 |
Weighted Average Remaining Contractual Term (years), Outstanding Beginning | 9 months 3 days |
Aggregated Intrinsic Value, Outstanding Beginning Balance | $ | |
Stock Option Outstanding, Granted | shares | |
Weighted Average Exercise Price, Granted | $ / shares | |
Weighted Average Remaining Contractual Term (years), Granted | |
Aggregated Intrinsic Value, Outstanding, Granted | $ | |
Stock Option Outstanding, Cancelled | shares | |
Weighted Average Exercise Price, Cancelled | $ / shares | |
Weighted Average Remaining Contractual Term (years), Cancelled | |
Aggregated Intrinsic Value, Outstanding, Cancelled | $ | |
Stock Option Outstanding, Exercised | shares | |
Weighted Average Exercise Price, Exercised | $ / shares | |
Weighted Average Remaining Contractual Term (years), Exercised | |
Aggregated Intrinsic Value, Outstanding, Exercised | $ | |
Stock Option Outstanding, Ending Balance | shares | 513,730 |
Weighted Average Exercise Price, Ending Balance | $ / shares | $ 1.43 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 3 months 3 days |
Aggregated Intrinsic Value, Outstanding Ending | $ | |
Stock Option Outstanding, Exercisable Ending Balance | shares | 513,730 |
Weighted Average Exercise Price, Exercisable Ending Balance | $ / shares | $ 1.43 |
Weighted Average Remaining Contractual Term (years), Exercisable | 3 months 3 days |
Aggregated Intrinsic Value, Exercisable Ending | $ |
Schedule of Warrants Outstandin
Schedule of Warrants Outstanding (Details) - Warrant [Member] | 6 Months Ended |
Jun. 30, 2022 $ / shares shares | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |
Shares Outstanding, Beginning Balance | shares | 22,200 |
Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares | $ 59.25 |
Weighted Average Remaining Contractual Term (years), Outstanding Beginning | 3 months 25 days |
Shares, Granted | shares | |
Weighted-Average Exercise Price, Granted | $ / shares | |
Shares, Cancelled | shares | (20,200) |
Weighted average Exercise price, Cancelled | $ / shares | $ 60.17 |
Shares, Exercised | shares | |
Weighted-Average Exercise Price, Exercised | $ / shares | |
Shares Outstanding, Ending Balance | shares | 2,000 |
Weighted-Average Exercise Price, Outstanding Ending Balance | $ / shares | $ 50 |
Weighted Average Remaining Contractual Term (years), Outstanding Ending | 8 months 19 days |
Shares Exercisable, Ending Balance | shares | 2,000 |
Weighted-Average Exercise Price, Exercisable Ending Balance | $ / shares | $ 50 |
Weighted Average Remaining Contractual Term (years), Exercisable Ending | 8 months 19 days |
Shareholders_ Deficit (Details
Shareholders’ Deficit (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||||||||
Jan. 29, 2020 | Dec. 22, 2017 | Feb. 07, 2017 | Feb. 22, 2013 | Jun. 30, 2022 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Nov. 11, 2019 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Stock Issued During Period, Shares, Issued for Services | 62,250,000 | |||||||||
Stock Issued During Period, Value, Issued for Services | $ 1,281,900 | $ 1,281,900 | ||||||||
Stock Issued During Period, Value, New Issues | $ 126,000 | |||||||||
Share-based compensation expenses | $ 40,961 | |||||||||
Former Related Party [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Issuance of common stock | 2,505,834 | |||||||||
Stock Issued During Period, Value, New Issues | $ 84,697 | |||||||||
Promissory Notes [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Accrued interest | $ 91,485 | |||||||||
Issuance of common stock | 2,500,334 | |||||||||
Settlement of Debt [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Issuance of common stock | 4,020,986 | |||||||||
Stock Issued During Period, Value, New Issues | $ 142,424 | |||||||||
Purchase Agreement [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Issuance of common stock | 1,050,000 | 7,000,000 | ||||||||
Stock Issued During Period, Value, New Issues | $ 126,000 | |||||||||
One Investor [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Issuance of common stock | 2,428,777 | |||||||||
Series AA Preferred Stock [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Number of shares outstanding | 1,000,000 | |||||||||
Preferred stock, par value | $ 0.001 | |||||||||
Preferred stock voting rights | Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company | |||||||||
Preferred stock, shares outstanding | 25,000 | 25,000 | ||||||||
Series B Convertible Preferred Stock [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Number of shares outstanding | 50,000 | 50,000 | 50,000 | 50,000 | ||||||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||
Preferred stock, shares outstanding | 600 | 600 | 600 | |||||||
Stated value dividend | 75% | |||||||||
Warrants term | three-year | |||||||||
Share exercise price | 150% | |||||||||
Liquidation value of preferred stock, per share | $ 100 | |||||||||
Series C Convertible Redeemable Preferred Stock [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Number of shares outstanding | 8,000 | |||||||||
Preferred stock, shares outstanding | 738 | 738 | ||||||||
Liquidation value of preferred stock, per share | $ 1,000 | $ 1,000 | $ 1,000 | |||||||
Preferred stock, dividend per share | $ 20 | |||||||||
Change in rights due to amendment and restated certificate, description | the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock | |||||||||
Series D Convertible Preferred Stock [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Number of shares outstanding | 20,000 | 20,000 | 20,000 | 20,000 | ||||||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||
Preferred stock, shares outstanding | 305 | 305 | 305 | |||||||
Liquidation value of preferred stock, per share | $ 1,000 | $ 1,000 | ||||||||
Conversion price | 0.01% | |||||||||
Preferred Stock Designated [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Number of shares outstanding | 5,000,000 | 5,000,000 | ||||||||
Common Stock [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Shares issued for conversion of notes payable, shares | 10,200,000 | 21,490,651 | ||||||||
Shares issued for conversion of notes payable | $ 93,796 | $ 374,335 | ||||||||
Accrued interest | $ 110,204 | $ 110,204 | ||||||||
Issuance of common stock | 7,000,000 | |||||||||
Stock Issued During Period, Shares, Issued for Services | 62,250,000 | |||||||||
Stock Issued During Period, Value, Issued for Services | $ 6,225 | |||||||||
Stock Issued During Period, Value, New Issues | $ 700 | |||||||||
Conversion Of Series C Common Stock [Member] | ||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||
Issuance of common stock | 1,111,111 | |||||||||
Stock Issued During Period, Value, New Issues | $ 33,333 |
Related Party and former rela_2
Related Party and former related parties Transactions (Details Narrative) - USD ($) | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||
Repayment of debt | $ 6,500 | $ 22,000 | |
Notes Payable, Related Parties, Current | 119,600 | $ 126,100 | |
Interest Payable, Current | 3,032,796 | $ 2,528,459 | |
Executive Officer [Member] | |||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||
Deferred compensation | 454,818 | ||
Accrual deferred compensation | 150,000 | ||
Cash repayments of deferred compensation | 89,000 | ||
Advance from officer | 5,662 | ||
Repayment of debt | 4,862 | ||
One Former Executive Officer [Member] | |||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||
Deferred compensation | 632,257 | ||
Officer [Member] | |||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||
Due to officer | 925 | ||
Former President [Member] | |||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||
Notes Payable, Related Parties, Current | 119,600 | ||
Interest Payable, Current | $ 74,180 |
Schedule of Conversion Feature
Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details) | 6 Months Ended | |
Jun. 30, 2022 $ / shares | Jun. 30, 2021 $ / shares | |
Measurement Input, Expected Term [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, term | 1 month | |
Measurement Input, Expected Term [Member] | Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, term | 1 month | |
Measurement Input, Expected Term [Member] | Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, term | 4 months | |
Measurement Input, Exercise Price [Member] | Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, percentage | 0.004 | 0.012 |
Measurement Input, Exercise Price [Member] | Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, percentage | 0.015 | 0.028 |
Measurement Input, Price Volatility [Member] | Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, percentage | 1.53 | 1.82 |
Measurement Input, Price Volatility [Member] | Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, percentage | 1.69 | 2.06 |
Measurement Input, Expected Dividend Rate [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, percentage | 0 | 0 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, percentage | 0.0163 | 0.0007 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, percentage | 0.0280 | 0.0013 |
Forfeitures [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value assumptions, measurement input, percentage | 0 | 0 |
Schedule of Fair Value of Deriv
Schedule of Fair Value of Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] | 6 Months Ended |
Jun. 30, 2022 USD ($) | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Derivative Liability, beginning | $ 3,442,297 |
Extinguishment | |
Change in estimated fair value | 1,846,964 |
Derivative Liability, ending | $ 5,289,261 |
Schedule of Liabilities Signifi
Schedule of Liabilities Significant Unobservable Inputs (Details) | Jun. 30, 2022 USD ($) |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Derivative liability | $ 5,289,261 |
Total | 5,289,261 |
Fair Value, Inputs, Level 1 [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Derivative liability | |
Total | |
Fair Value, Inputs, Level 2 [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Derivative liability | |
Total | |
Fair Value, Inputs, Level 3 [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Derivative liability | 5,289,261 |
Total | $ 5,289,261 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - Auctus Fund, LLC [Member] | 1 Months Ended |
Aug. 31, 2019 USD ($) | |
Other Unspecified Damages And Attorney Fees [Member] | |
Loss Contingencies [Line Items] | |
Loss Contingency, Damages Sought, Value | $ 500,000 |
Note [Member] | |
Loss Contingencies [Line Items] | |
Loss Contingency, Damages Sought, Value | $ 275,250 |
Concentrations (Details Narrati
Concentrations (Details Narrative) | 6 Months Ended |
Jun. 30, 2022 | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Significant Customers [Member] | |
Concentration Risk [Line Items] | |
Concentration risk, percentage | 72% |
Revenue Benchmark [Member] | Supplier Concentration Risk [Member] | Supplier [Member] | |
Concentration Risk [Line Items] | |
Concentration risk, percentage | 100% |
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member] | |
Concentration Risk [Line Items] | |
Concentration risk, percentage | 100% |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - Subsequent Event [Member] | 2 Months Ended |
Aug. 16, 2022 USD ($) shares | |
Subsequent Event [Line Items] | |
Convertible promissory note | $ | $ 150,000 |
Investor [Member] | |
Subsequent Event [Line Items] | |
Issuance of common stock | shares | 2,050,000 |